Higher Lp(a) Threshold More Closely Linked to Major ASCVD Events

New data suggest that cardiovascular risk associated with elevated lipoprotein(a) [Lp(a)] becomes clinically significant at a higher level than currently emphasized in guidelines. 

An analysis of three large randomized controlled trials indicates that Lp(a) ≥ 175 nmol/L, rather than the commonly referenced ≥ 125 nmol/L, is an independent predictor of all‑cause mortality, cardiovascular death, and stroke, even after adjustment for traditional risk factors. 

The magnitude of excess risk approaches that associated with active smoking.

Evidence From Large RCT Cohorts

The analysis included 20,070 patients drawn from the ACCORD, PEACE, and SPRINT trials (mean age 65 years; 35% women). Participants were stratified by Lp(a) level (< 75, 75–125, 125–175, or ≥ 175 nmol/L) and by primary versus secondary prevention status. Roughly one quarter had prior coronary revascularization, one fifth had a history of myocardial infarction, and a smaller proportion had prior stroke.

Over a median follow‑up of approximately four years, the overall rate of major adverse cardiovascular events (MACE) was 7.3%. MACE rates were similar across Lp(a) categories below 175 nmol/L but increased to 8.1% among those with Lp(a) ≥ 175 nmol/L. In adjusted survival analyses, this highest Lp(a) group demonstrated significantly lower MACE‑free survival, particularly among patients with established cardiovascular disease.

Stronger Signal in Secondary Prevention

Multivariable modeling over seven years confirmed that Lp(a) ≥ 175 nmol/L was independently associated with higher MACE risk, with hazard ratios approaching those seen with current smoking. The association was statistically significant in secondary prevention patients, while it was weaker and not significant in primary prevention. Consistent with this, population‑attributable risk was nearly twice as high in secondary versus primary prevention cohorts.

When analyzed as a continuous variable, Lp(a) showed a gradual risk increase above 125 nmol/L, followed by a steeper rise at levels ≥ 175 nmol/L. Importantly, no independent association was seen between elevated Lp(a) and myocardial infarction, suggesting that excess risk is driven largely by stroke and mortality outcomes.

Implications for Guidelines and Emerging Therapies

Current ACC/AHA dyslipidemia guidelines consider Lp(a) ≥ 125 nmol/L a risk‑enhancing factor, primarily to justify more intensive LDL‑cholesterol lowering and risk‑factor management. While these recommendations remain valid, the new findings suggest that clinically dominant residual risk concentrates at higher Lp(a) levels, particularly in secondary prevention populations.

This threshold is notable given several ongoing cardiovascular outcomes trials testing Lp(a)‑lowering therapies, including small interfering RNA and antisense approaches. These trials use entry thresholds around or above this range, reflecting growing consensus that markedly elevated Lp(a) identifies patients most likely to benefit from targeted intervention.

Practical Takeaways for Clinicians

Until dedicated Lp(a)‑lowering therapies become clinically available, these findings support several pragmatic steps:

• Routine (once‑in‑a‑lifetime) Lp(a) testing, especially in patients with premature or unexplained ASCVD
• Recognition of Lp(a) ≥ 175 nmol/L as a marker of particularly high residual risk, most relevant in secondary prevention
• Aggressive optimization of modifiable risk factors, including LDL‑cholesterol, blood pressure, and lifestyle measures
• Consideration of additional risk stratification tools, such as coronary artery calcium scoring, when values approach high‑risk thresholds

Bottom Line

Lp(a) continues to emerge as a major contributor to residual cardiovascular risk. This large, well‑characterized analysis suggests that 175 nmol/L may represent the most clinically meaningful cutoff for predicting death and stroke, particularly in patients with established disease. As targeted Lp(a) therapies advance, refining how we interpret and act on Lp(a) levels today will be critical for translating future treatments into improved outcomes.

Source: Banerjee S. Lipoprotein(a) identifies residual cardiovascular risk in NIH randomized trials. Presented at SCAI 2026, Montreal, Canada.